Strain mass-producing .epsilon.-poly-L-lysine

Abstract

The present invention provides mutants mass-producing .epsilon.PL which are obtained by mutation treatment of a strain producing .epsilon.PL. For using the mutants, the mutants are cultured in a cultivated medium, .epsilon.PL is mass-produced and stored in the culture solution, and the stored .epsilon.PL is collected from the solution. For producing .epsilon.PL, a strain which produces .epsilon.PL is mutation-treated, the obtained mutant is cultivated in a culture medium to which L-lysine or L-lysine and one or more sugars are added, .epsilon.PL is mass-produced and stored in the culture solution, and the stored .epsilon.PL is collected from the solution. The mutants producing .epsilon.PL in large quantities are preferably the mutants which have tolerance to an analogue of L-lysine of Streptomyces albulus subsp. lysinopolymerus No. 346-D strain and chloramphenicol-treated mutant of the same bacteria.

Dependencies are inferred from the claim text.